Geron (GERN) Change in Accured Expenses (2010 - 2026)
Geron's (GERN) quarterly Change in Accured Expenses came in at -$20.4 million in Q1 2026, down 54.3% year-on-year from -$44.6 million in Q1 2025, and down 228.11% quarter-over-quarter from $15.9 million in Q4 2025.
Geron (GERN) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Geron has disclosed Change in Accured Expenses across 17 years of filings, most recently posting -$20.4 million for Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$20.4 million, down 54.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.6 million (up 54.81% YoY), and the FY2025 annual result was $15.8 million, up 74.49% from the prior year.
- Change in Accured Expenses came in at -$20.4 million for Q1 2026 at Geron, down from $15.9 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $28.0 million in Q3 2022 to a low of -$20.5 million in Q4 2022.
- The 5-year median for Change in Accured Expenses is $967000.0 (2022), against an average of $595529.4.
- Across the five-year window, Change in Accured Expenses surged 1980.45% in 2022 and slumped 1340.64% in 2023, its largest moves.
- Geron's Change in Accured Expenses stood at -$20.5 million in 2022, then soared by 56.68% to -$8.9 million in 2023, then surged by 149.68% to $4.4 million in 2024, then jumped by 261.29% to $15.9 million in 2025, then tumbled by 228.11% to -$20.4 million in 2026.
- The last three Change in Accured Expenses figures came in at -$20.4 million (Q1 2026), $15.9 million (Q4 2025), and $21.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Geron | 729,618.77 | 729,618.77 | - | -20.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.37 Mn |
| Mar 31, 2026 | -20.37 Mn |
| Dec 31, 2025 | 15.90 Mn |
| Dec 31, 2025 | 15.90 Mn |
| Sep 30, 2025 | 21.37 Mn |
| Sep 30, 2025 | 21.37 Mn |
| Jun 30, 2025 | -8.28 Mn |
| Jun 30, 2025 | -8.28 Mn |
| Mar 31, 2025 | -13.20 Mn |
| Mar 31, 2025 | -13.20 Mn |
| Dec 31, 2024 | 4.40 Mn |
| Dec 31, 2024 | 4.40 Mn |
| Sep 30, 2024 | 9.56 Mn |
| Sep 30, 2024 | 9.56 Mn |
| Jun 30, 2024 | 4.81 Mn |
| Jun 30, 2024 | 4.81 Mn |
| Mar 31, 2024 | -9.72 Mn |
| Mar 31, 2024 | -9.72 Mn |
| Dec 31, 2023 | -8.86 Mn |
| Dec 31, 2023 | -8.86 Mn |